Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression by Gamal Badr et al.
RESEARCH Open Access
Thymoquinone decreases F-actin polymerization
and the proliferation of human multiple myeloma
cells by suppressing STAT3 phosphorylation and
Bcl2/Bcl-XL expression
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Abstract
Background: Thymoquinone (TQ), the major active component of the medicinal herb Nigella sativa Linn., has
been described as a chemopreventive and chemotherapeutic compound.
Methods: In this study, we investigated the effect of TQ on survival, actin cytoskeletal reorganization, proliferation
and signal transduction in multiple myeloma (MM) cells.
Results: We found that TQ induces growth arrest in both MDN and XG2 cells in a dose- and time-dependent
manner. TQ also inhibited CXC ligand-12 (CXCL-12)-mediated actin polymerization and cellular proliferation, as
shown by flow cytometry. The signal transducer and activator of transcription (STAT) and B-cell lymphoma-2 (Bcl-2)
signaling pathways may play important roles in the malignant transformation of a number of human malignancies.
The constitutive activation of the STAT3 and Bcl-2 pathways is frequently observed in several cancer cell lines,
including MM cells. Using flow cytometry, we found that TQ markedly decreased STAT3 phosphorylation and Bcl-2
and Bcl-XL expression without modulating STAT5 phosphorylation in MM cells. Using western blotting, we
confirmed the inhibitory effect of TQ on STAT3 phosphorylation and Bcl-2 and Bcl-XL expression.
Conclusions: Taken together, our data suggests that TQ could potentially be applied toward the treatment of MM
and other malignancies.
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Background
Multiple myeloma (MM) is a monoclonal plasma cell
malignancy that, despite intensive investigation, remains
universally fatal [1]. Clinically, it is characterized by high
levels of paraproteins in the blood and/or urine, lytic
bone lesions, anemia, renal dysfunction, and bone mar-
row (BM) plasmacytosis [2]. Current treatments for this
disease include combination chemotherapy with or with-
out stem cell transplantation and the use of alkylating
agents, glucocorticosteroids, and thalidomide [3]. There-
fore, there is a need to further identify the factors and
mechanisms responsible for maintaining the survival
and proliferation of MM cells and mediating tumorigen-
esis and drug resistance. Previous studies have reported
that MM cell proliferation is a prognostic factor and is
associated with angiogenesis [4]. The actin cytoskeleton
and its regulatory proteins are crucial for the migration
of most cells. During cell migration, the actin cytoskele-
ton is dynamically remodeled, which produces the force
necessary for cell migration [5]. Because inhibiting these
processes decreases cell motility, elucidating the molecu-
lar mechanisms of actin reorganization is important for
cancer therapeutics. Chemokines, such as CXCL-12, and
its receptor CXCR4, have been shown to be involved in
the homing and migration of MM cells by attracting
and activating plasma cells in the BM [6].
The signal transducer and activator of transcription
(STAT) family of transcription factors is associated with
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inflammation and the survival, proliferation, metastasis,
angiogenesis, and chemoresistance of tumor cells [7].
The STAT3 and STAT5 transcription factors have been
implicated in numerous malignancies. They are the final
targets of IL-6 and IGF-1, respectively, and can stimu-
late the growth of B cells [8]. STAT3 is constitutively
expressed in MM, leukemia, lymphoma, squamous cell
carcinoma, and other solid tumors, including cancers of
the prostate, breast, head and neck, and nasopharynx
[7]. STAT3 may also promote tumor cell transformation
via anti-apoptotic signaling (i.e., by up-regulating the
genes that counteract active cell death). In cell lines
from brain, skin, and breast tumors, the overexpression
of anti-apoptotic genes, such as Bcl-2 and Bcl-XL, is
associated with constitutive STAT3 activity, and STAT3
inhibition induces apoptosis [9-11]. The inhibition of
signal mediators acting upstream of STAT3 and the use
of dominant-negative variants of STAT3 have been
shown to reduce proliferation or enhance apoptosis in
various cell types [12,13].
Thymoquinone (TQ) is considered to be the bioactive
and the most abundant constituent of volatile black seed
oil and has been shown to have anti-inflammatory and
antioxidant effects [14]. In particular, Shoieb et al.
[2003] found in vitro inhibition of growth and induction
of apoptosis in cancer cell lines in response to TQ [15].
In addition, TQ has the ability to kill several types of
tumors without significant toxicity to normal cells, indi-
cating that this compound may be a potential che-
motherapeutic agent [16]. Recently, Ravindran et al.
[2010] published a detailed study of the anti-prolifera-
tive, anti-inflammatory and chemosensitization activities
of TQ in myeloid leukemia cells [17]. Although most of
their data focused on myeloid leukemia cells, they com-
pared the effect of TQ on cells from various types of
cancers. Furthermore, it has been reported that TQ
inhibits proliferation, induces apoptosis and chemosensi-
tizes human MM cells by suppressing the signal trans-
ducer and activator of the transcription 3 activation
pathway [18]. Thus, TQ exerts an anti-neoplastic effect
and may be a promising dietary chemopreventive agent.
Although TQ modulates proliferation and induces
growth arrest in numerous cancer cells, few data are
available concerning its effect on MM cells. Therefore,
in this study, we investigated the effect of TQ on survi-
val, actin cytoskeletal reorganization, proliferation and
signal transduction in MM cells.
Materials and methods
Cell culture and reagents
MDN and XG-2 cells are IL-6-dependent human mye-
loma cells [19,20]. These MM cells were maintained in
RPMI 1640 medium containing 10 mM HEPES, 10%
fetal calf serum (FCS; BioWhittaker, Walkersville, MD,
USA) and 1% L-glutamate (R-10 medium) supplemented
with 3 ng/mL IL-6 (Peprotech, Rocky Hill, NJ, USA).
The cell cultures were free of Mycoplasma, as assessed
by an enzyme-linked immunosorbent assay (ELISA) kit
(Boehringer, Mannheim, Germany). All aspects of this
study were approved by ethical committee according to
the Declaration of Helsinki.
Anti-proliferation assay
The anti-proliferative effect of TQ on MDN and XG2
cells was determined using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) uptake
method. Briefly, 5 × 104 cells/well were plated on 48-
well culture plates and allowed to adhere at 37°C for 12
h. The following day, various doses of TQ were added
to the cells, which were further incubated for 12 h.
Next, MTT (0.5 mg) was added to 1 mL of the cell sus-
pension for 4 h. The ability of the cells to form forma-
zan crystals via active mitochondrial respiration was
determined using a microplate reader (Titertek Multis-
kan, Flow Laboratories, North Ryde, Austria) after dis-
solving the crystals in DMSO. An empty well was used
as a blank. Cytotoxicity was expressed as the relative
percentage of the absorbance measured in the control
and TQ-treated cells. Morphological changes after expo-
sure to the TQ extract were observed under a phase-
contrast inverse microscope (Olympus, Japan).
F-actin polymerization assay
MM cells were cultured for 24 h in culture medium
with or without TQ. Intracellular F-actin polymerization
was assessed as previously described [21]. Briefly, the
cells were harvested and resuspended (4 × 106/ml) in
HEPES-buffered RPMI 1640 at 37°C with or without
CXCL-12 (250 ng/ml). At the indicated times, the cells
(100 μl) were added to 400 μl of assay buffer containing
4 × 10-7 M FITC-labeled phalloidin, 0.5 mg/ml L-a-
lysophosphatidylcholine (both from Sigma-Aldrich) and
4.5% formaldehyde in PBS. The fixed cells were analyzed
using flow cytometry, and the mean fluorescence inten-
sity (MFI) was determined for each sample. The percen-
tage change in the MFI was calculated for each sample
at each time point using the following formula: (1-(MFI
before addition of CXCL-12/MFI after addition of
CXCL-12) × 100.
CFSE proliferation assays
MM cells were harvested, washed twice in PBS and
stained with 0.63 μM carboxyfluorescein diacetate succi-
nimidyl ester (CFSE) (Molecular Probes, Eugene, OR,
USA) for 8 min at room temperature. The residual
CFSE was removed by washing three times in PBS, and
the CFSE-labeled cells were seeded in 6-well plates. The
cells were then grown for 5 days in cell culture medium
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with or without TQ (10 μM). The CFSE fluorescence
intensity was measured using FACS.
Intracellular phospho-specific flow cytometry
MM cells (with or without TQ treatment) were fixed for
10 minutes in pre-warmed cytofix buffer (BD Cytofix
#554655). The cells were permeabilized for 30 minutes
on ice in PERM III buffer (BD PERM-III buffer
#558050). The permeabilized cells were washed twice,
re-suspended in staining buffer (PBS plus 0.5% bovine
serum albumin), and stained in a final volume of 100 μL
for 30 min at room temperature. STAT3 and STAT5
phosphorylation, Bcl-2 and Bcl-XL expression and con-
trol IgG quantification were assessed in the cells using
the Phosflow method (BD Biosciences), according to the
manufacturer’s instructions. The cells were fixed and
directly analyzed using a FACSCalibur (BD
Pharmingen).
Immunoblotting
Whole-cell lysates were prepared from TQ-treated and
untreated cells in RIPA buffer (20 mM Tris-HCl, pH
7.5, 120 mM NaCl, 1.0% Triton 6100, 0.1% SDS, 1%
sodium deoxycholate, 10% glycerol, 1 mM EDTA and
1% protease inhibitor cocktail (Roche)). Following cen-
trifugation at 16,000 × g at 4°C for 15 min, the protein
concentrations in the supernatants were determined
using a protein assay kit (Bio-Rad, Hercules, CA, USA).
Equal amounts of protein from the whole-cell lysates
were mixed with reducing sample buffer (0.92 M Tris-
HCl, pH 8.8, 1.5% SDS, 4% glycerol, and 280 mM 2-
ME) and separated using discontinuous SDS-PAGE. The
Figure 1 Dose and time responses of cell death after TQ treatment. Five thousand MDN (A) and XG2 (B) cells, per well were seeded in
triplicate onto 96-well plates; treated with different concentrations of TQ at 0, 1, 2, 5, 10, 20 and 50 μM for overnight; measured cell viability by
the MTT method and presented as percent cell viability. (C) the cells were treated for different incubation hours with the representative IC50 of
TQ. Data are the representative of three independent experiments, and are presented as the mean percentage of viable cells ± SEM.
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proteins were transferred onto nitrocellulose membranes
using a Bio-Rad Trans-Blot electrophoretic transfer
device and blocked for 1 h at room temperature with
1% BSA or 5% skim milk dissolved in TBS (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl) supplemented with
0.1% Tween 20. The membranes were then incubated in
the same blocking buffer with rabbit polyclonal antibo-
dies to STAT3 and STAT5 and mouse monoclonal anti-
bodies against phosphorylated STAT3 (Tyr705) and
phosphorylated STAT5, Bcl-2 and Bcl-XL (1:1,000; all
from Santa Cruz Biotechnology). The blots were rinsed
thoroughly and then incubated with an HRP-labeled
species-matched secondary antibody for 1 h. The pro-
tein bands were detected using enhanced chemilumines-
cence reagents (ECL, SuperSignal West Pico
Chemiluminescent Substrate, Perbio, Bezons, France),
and the ECL signals were visualized using hyperfilm
ECL. To quantify the band intensities, the films were
scanned, saved as TIFF files and analyzed using NIH
ImageJ. The percentages of STAT3 and STAT5 phos-
phorylation, as well as the percentages of Bcl-2 and Bcl-
XL expression were calculated as the intensities of pro-
tein bands relevant to the corresponding actin bands ×
100.
Statistical analyses
The data were analyzed using the SPSS software (ver-
sion 16) and expressed as means ± SEM. The differ-
ences between the groups were assessed using analysis
of variance (ANOVA). Differences were considered sig-
nificant if the calculated p-values were less than 0.05.
Results
Inhibition of cell viability in response to TQ treatment
We first investigated the ability of TQ to induce growth
arrest in the MM cell lines MDN and XG2. These cells
were treated overnight with different doses of TQ, and
the cytotoxic effect of TQ was measured using the MTT
uptake method. We found that TQ induced growth
arrest in these cells in a dose-dependent manner, with
IC50 values of 10 μM for MDN (Figure 1 A) and 8.5 μM
for XG2 (Figure 1B; p < 0.05; n = 3). Furthermore, TQ
significantly inhibited the growth of MDN and XG2
cells in a time-dependent manner. This effect was
apparent after incubation for 2 hours, peaked after 12 h
and decreased thereafter (Figure 1C; p < 0.05; n = 3).
TQ inhibits CXCL-12-mediated actin polymerization
Actin and microtubules provide a dynamic cellular fra-
mework to orchestrate and ultimately control cellular
activation and cancer metastasis. Therefore, we moni-
tored actin polymerization in response to CXCL-12 sti-
mulation in MDN and XG2 cells. The cells were
cultured for 12 hours in the presence or absence of TQ
prior to stimulation with CXCL-12 (250 ng/ml) every 15
sec. The degree of F-actin polymerization was deter-
mined using flow cytometry. In untreated control MDN
cells (closed squares), the percentage of F-actin poly-
merization was 89 ± 6.4%, 68 ± 5.6%, 30 ± 2.8% and 7 ±
1% after 15, 30, 45 and 60 sec, respectively. However,
the percentage of F-actin polymerization was signifi-
cantly reduced to 58 ± 5.1%, 27 ± 3.5%, 15 ± 1.3% and 9
± 0.85% after 15, 30, 45 and 60 sec, respectively, in TQ-
treated cells (open squares, Figure 2A; p < 0.05; n = 5).
Similarly, the percentage of F-actin polymerization in
untreated control XG2 cells (closed circles) was 77 ±
7.1%, 50 ± 4.8%, 19 ± 1.5% and 5 ± 0.7% after 15, 30, 45
and 60 sec, respectively. However, in TQ-treated cells,
the percentage of F-actin polymerization was signifi-
cantly reduced to 51 ± 4.9%, 17 ± 2.1%, 11 ± 1% and 1
± 0.8% after 15, 30, 45 and 60 sec, respectively (open
circles, Figure 2B; p < 0.05; n = 5).
Figure 2 Effects of TQ on CXCL-12-mediated F-actin
polymerization. MDN (A) and XG2 (B) cells were untreated (open
symbols) or treated with TQ for 12 hr (black symbols). F-actin
polymerization in response to CXCL-12 was measured. The results
are expressed as the percentage change in MFI (n = 5) ± SEM, as
described in the Materials and Methods section.
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TQ inhibits IL-6-induced proliferation in MM cells
IL-6 plays a major role in the development and mainte-
nance of MDN and XG2 cells. Therefore, we monitored
the effects of TQ on IL-6-mediated MDN and XG2 cell
proliferation using a CFSE dilution assay and flow cyto-
metry. As shown in Figure 3, the percentage of prolifer-
ating MDN cells was markedly reduced from 74% in the
medium-treated cells (Figure 3A) to 49% in the TQ-
treated cells (Figure 3B). Similarly, the percentage of
proliferating XG2 cells was markedly reduced from 81%
in the medium-treated cells (Figure 3D) to 44% in the
TQ-treated cells (Figure 3E). Our data revealed that the
proliferative capacity of MDN cells was significantly
reduced from 73 ± 5.8% in the medium-treated cells to
47 ± 4.4% in the TQ-treated cells (Figure 3C; p < 0.05;
n = 5). Similarly, TQ treatment significantly reduced IL-
6-mediated XG2 cell proliferation from 86 ± 6.4% in the
medium-treated cells to 52 ± 5.1% in the TQ-treated
cells (Figure 3F; p < 0.05; n = 5).
TQ suppresses phosphorylation of STAT3 and its
downstream signaling effectors Bcl-2 and Bcl-XL
We investigated whether TQ treatment impairs signaling
by STAT3, a signaling transcription factor important for
MM cell maintenance and survival. Using Phosflow
assays and flow cytometry, we found that TQ markedly
decreased STAT3 phosphorylation (Figure 4A) but had
no effect on STAT5 phosphorylation (Figure 4B). STAT3
regulates several anti-apoptotic proteins, including Bcl-2,
Bcl-XL and survivin. We also found that TQ decreases
Bcl-2 (Figure 4C) and Bcl-XL (Figure 4D) expression.
Because antibodies directed against phospho-proteins
vary in their sensitivities depending on the technique,
we confirmed our results using antibodies against
pSTAT3, pSTAT5, Bcl-2 and Bcl-XL and western blot-
ting. Figures 5A and 5C show the data obtained in one
representative experiment out of five experiments per-
formed in MDN and XG2 cells. The levels of phos-
phorylated STAT3 and STAT5 and the expression of
Bcl-2 and Bcl-XL were normalized to the amount of
total b-actin in five separate experiments. In MDN cells
(Figure 5B), STAT3 phosphorylation and the expression
of Bcl-2 and Bcl-XL were significantly diminished from
152 ± 11.7%, 142 ± 11.3% and 109 ± 7.9% in untreated
cells to 30 ± 2.8%, 12 ± 1.1% and 37 ± 3.3% in TQ-trea-
ted cells, respectively (p < 0.05; n = 5). Although
STAT5 was clearly phosphorylated in both TQ-treated
and untreated cells, TQ had no effect on STAT5 phos-
phorylation. Similarly, STAT3 phosphorylation and the
expression of Bcl-2 and Bcl-XL were significantly
reduced from 130 ± 7.1%, 97 ± 6.7% and 132 ± 8.2% in
untreated XG2 cells to 26 ± 2.5%, 13 ± 1.1% and 35 ±
3.4% in TQ-treated XG2 cells, respectively (Figure 5D; p
< 0.05; n = 5).
Discussion
Although the anti-tumor and cytotoxic effects of TQ on
numerous cancer cells have been known for many years
Figure 3 TQ diminishes IL-6-induced proliferation of MM cells. The ability of MDN (A, B, C) and XG2 (A, E, F) cells to proliferate in the
presence or absence of TQ was evaluated using CFSE assays and flow cytometry. CFSE-labeled cells were then left untreated (medium-treated
cells) (A, D) or treated with TQ (B, E). One representative experiment of five showing that histograms were gated on viable cells, and the mean
of the left histograms represents the percentage of CFSE-lo (proliferating) cells. Combined data from 5 different experiments are expressed as
the mean percentage of proliferating MDN (C) and XG2 (F) cells ± SEM, * p < 0.05.
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[14,22-24], little is known regarding its effects on MM
cells. Here, we investigated the effects of TQ on two dif-
ferent MM cell lines (MDN and XG2). Proliferation and
survival are critically important for tumor growth and
metastatic spreading; therefore, proliferation and survi-
val have been attractive targets for tumor therapy. First,
we assessed the ability of TQ to induce growth arrest in
the MM cell lines MDN and XG2, and we found that
TQ induces growth arrest in both MDN and XG2 cells
in a dose- and time-dependent manner. Our results
agree with the results of Shoieb et al., [2003] who attrib-
uted this growth inhibition to apoptosis and cell cycle
arrest [15]. Cell migration is a critical step in tumor
invasion and metastasis, and regulation of this process
may lead to appropriate therapies for treating cancer.
Actin cytoskeletal reorganization is the primary mechan-
ism of cell motility and is essential for most types of
cancer cell migration [25]. Therefore, we monitored
actin polymerization in response to CXCL-12 stimula-
tion and found that TQ decreases CXCL-12-mediated
actin polymerization in MDN and XG2 cells. Indeed,
previous studies have suggested the involvement of
CXCL12/CXCR4 in the maintenance and survival of
MM cells both in vivo and in vitro [6,26].
IL-6 is a pleiotropic cytokine with biological activities
in a wide variety of cells. Normally, IL-6 induces B-cell
differentiation, but in myeloma it induces proliferation
and inhibits apoptosis [27]. IL-6 is especially involved
in malignant plasma cell expansion. IL-6, which is
derived from both autocrine and paracrine sources, is
the key growth and survival factor for MM cells
[28,29]. Therefore, we investigated the effects of TQ
on IL-6-mediated MDN and XG2 cell proliferation
using a CFSE dilution assay and flow cytometry. We
found that TQ inhibits IL-6-induced proliferation of
MM cells, which agrees with previous results of Shoieb
et al., [2003] who reported that TQ inhibits tumor cell
proliferation through a mechanism that involves cyto-
toxicity [15]. In addition, previous studies have shown
that TQ inhibits cell proliferation in many types of
cancer cells [14]. Recently, Li et al., found that TQ
inhibits MM cell proliferation by suppressing the signal
transducer and activator of transcription 3 activation
pathway [18].
Members of the STAT family of transcription factors
regulate the expression of gene products involved in cell
survival, proliferation, chemoresistance, and angiogenesis
[7]. Previous studies have reported that STAT3 is con-
stitutively activated in a growing number of tumor-
derived cell lines and samples from human cancers,
including lymphomas and leukemias [8]. Furthermore, a
constitutively active STAT3 mutant has been shown to
induce cellular transformation in fibroblasts, which
reveals its oncogenic potential [30]. In MM cells,
STAT3 signaling has also been reported to play an
important role in cell maintenance and survival [31].
Our data demonstrate that TQ suppresses STAT3 phos-
phorylation and the expression of its downstream signal-
ing effectors Bcl-2 and Bcl-XL but has no effect on
STAT5 phosphorylation. Our results agree with those of
Li et al., [2010] who found that TQ down-regulates the
expression of STAT3-regulated gene products, such as
cyclin D1, Bcl-2, Bcl-XL, survivin, Mcl-1 and vascular
endothelial growth factor [18].
Figure 4 Flow cytometry quantification of phospho-STAT3,
phospho-STAT5 and expression of Bcl-2/Bcl-XL after TQ
treatment. Phosphorylation of STAT3 (A) and STAT5 (B) as well as
the anti-apoptotic molecules Bcl-2 (C) and Bcl-XL (D) in MDN (left
panel) and XG2 (right panel) cells were monitored after 12-hr
incubation in the presence or absence of TQ using Phosflow mAbs
and flow cytometric analysis. Histograms for medium-treated cells
are displayed as open bold line histograms, as gray-filled histograms
in TQ-treated cells, while the isotype controls are represented by
open dotted thin line histograms. One representative experiment of
three in shown.
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Conclusions
Our data reveal the anti-tumor effects of TQ. Therefore,
TQ administration is a new approach that can enhance
immunogenicity, reduce cell proliferation and increase
apoptosis in cancer cells by suppressing STAT3 phos-
phorylation and Bcl-2/Bcl-XL expression.
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